Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.

Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience

Open access
Steinhoff, Bernhard J., Staack, Anke M. · 2019 · Therapeutic Advances in Neurological Disorders

Abstract

Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (BRV) are pyrrolidone derivate compounds binding at the presynaptic SV2A receptor site and are thus representative of AEDs with a unique mode of action. LEV was extensively investigated in randomized controlled trials and has a very promising efficacy both in focal and generalized epilepsies. Its pharmacokinetic profile is favorable and LEV does not undergo clinically relevant interactions. Adverse reactions comprise mainly asthenia, somnolence, and behavioral symptoms. It has now been established as a first-line antiepileptic drug. BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756286419873518

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 144 references

Research works printed but not linked: 13

  1. 10.1111/j.1527-3458.2005.tb00268.x · DOI · Paper page
  2. De Smedt T, 2007, et al., 13, 57
  3. Ulloa CM, 2009, Neuropsychiatr Dis Treat, 5, 467
  4. Perucca E, 2000, Epilepsia, 41, 150
  5. Klein P, 2018, Clin Pharmacol, 10, 1
  6. Hannestad J, 2016, Epilepsia, 57, 128
  7. Lacroix B, 2007, Epilepsia, 48, 333
  8. Otoul C, 2015, Poster presented at American Epilepsy Society 69th Annual meeting
  9. Detrait E, 2008, Epilepsia, 49
  10. Werhahn KJ, Epilepsia, 6, 450
  11. 10.1016/j.eplepsyres.2007.06.002 · DOI
  12. Buck ML., 2002, Pediatric Pharmacoth, 8, 1
  13. D’Souza J, 2012, Epilepsia, 53, P402

Cited by

See all 99

Metadata

Authors
Steinhoff, B. J., & Staack, A. M.
Affiliations
Diakonie Kork (DE)
Corresponding author
Steinhoff, Bernhard J.
Venue
Therapeutic Advances in Neurological Disorders
Published
2019-01
Volume
12
Pages
1756286419873518-1756286419873518
ISSN
  • 1756-2856 (ISSN-L)
  • 1756-2864
OpenAlex
W2973225802
Cited by
99
References
144
Citations by year
2026: 17 · 2025: 9 · 2024: 17 · 2023: 12 · 2022: 15 · 2021: 19 · 2020: 8 · 2019: 1
FWCI
1.82
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Neurological Disorders (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
levetiracetam, brivaracetam, antiepileptic drugs, pyrrolidinone derivatives, focal epilepsy, generalized epilepsy, pharmacokinetics, drug interactions, adverse drug reactions, adjunctive therapy, first-line therapy, epilepsy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. https://app.cochat.ai/papers/10.1177/1756286419873518
The paper
Steinhoff, B. J., & Staack, A. M. (2019). Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756286419873518

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.